SAR 351034

Drug Profile

SAR 351034

Alternative Names: SAR3504; SAR351034

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Hyperlipidaemia; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia in France
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top